Stockscreener 앱 받기
0.9448
31.04%
-0.4252
시장 영업 전:
.82
-0.1248
-13.21%
Bioaffinity Technologies Inc 주식(BIAF)의 최신 뉴스
bioAffinity Technologies Warrant (BIAFW) Holds Steady at $0.16 as Trading Remains QuietRevenue Weighted - newsline.com
BIAF Q3 2025 Earnings: Wider-than-Expected Loss Misses EstimatesEarnings Miss Streak - newsline.com
BioAffinity Technologies Files to Offer 2.63M Shrs or Pre-Funded Warrants - Moomoo
BIAF News | BIOAFFINITY TECHNOLOGIES INC (NASDAQ:BIAF) - ChartMill
Bioaffinity TechnologiesOffers 2.63 Million Shares Of Common StockSEC Filing - TradingView
[S-1] bioAffinity Technologies, Inc. Files IPO Registration Statement - Stock Titan
BIAFW Holds Steady Amid Warrant Market Uncertainty: Support and Resistance in Tight RangeElliott Wave Entry - newsline.com
bioAffinity Technologies, Inc. - MLQ.ai
BIAF Stock Chart | BIOAFFINITY TECHNOLOGIES INC (NASDAQ:BIAF) - ChartMill
bioAffinity Technologies Stock Draws Fresh Attention From Traders - Bez Kabli
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar - BioSpace
bioAffinity Showcases CyPath Lung in Upcoming Clinical Webinar - TipRanks
bioAffinity webinar to showcase CyPath Lung's role in early-stage lung cancer detection - TradingView
bioAffinity Technologies (BIAF) spotlights CyPath Lung test in SAB lung cancer webinar - Stock Titan
BIAF Q3 2025 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues DevelopmentManagement Guidance Update - thelegaladvocate.com
bioAffinity Technologies (BIAF) Edges Higher Amidst Support Test – Potential for BreakoutGap Down Bounce Plays - newsline.com
BIAFW Warrants Trade Flat Near Support Amidst Quiet Market ConditionsEntry Point Alerts - newsline.com
bioAffinity Technologies (BIAF) Holds Steady at $1.65 as Consolidation PersistsTechnical Analysis Picks - newsline.com
bioAffinity receives patent allowance in Mexico for lung test - Investing.com UK
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology - BioSpace
bioAffinity receives patent allowance in Mexico for lung test By Investing.com - Investing.com Nigeria
bioAffinity Technologies notifies Mexico patent allowance for CyPath® Lung flow cytometry method - TradingView
Mexico backs bioAffinity (NASDAQ: BIAF) patent on CyPath Lung test - Stock Titan
bioAffinity Gains Mexican Patent for CyPath Lung Diagnostic - TipRanks
bioAffinity Technologies (BIAF) News Flow - Moomoo
Number of shareholders of bioAffinity Technologies, Inc. – NASDAQ:BIAF - TradingView
BIAF Q3 2025 Earnings: EPS Misses Estimates Amid No Revenue, Stock DeclinesEarnings Miss Streak - newsline.com
What's Driving bioAffinity Technologies' Recent Surge - Kavout
Top AIAI (AIAI) Competitors 2026 - MarketBeat
bioAffinity Technologies Inc (BIAF) Stock Price, Quote, News & History - Benzinga
BIAF Stock Price, Quote & Chart | BIOAFFINITY TECHNOLOGIES INC (NASDAQ:BIAF) - ChartMill
bioAffinity (BIAF) registers 497,483 resale shares, includes 365,603 warrants - Stock Titan
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung - The Globe and Mail
[EFFECT] bioAffinity Technologies, Inc. SEC Filing - Stock Titan
bioAffinity reports 300% jump in lung test sales in April - Investing.com UK
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Ye - PharmiWeb.com
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 - 01net
bioAffinity Technologies Reports Record 300% Growth in CyPath® Lung Diagnostic Test Sales in April 2026 - Minichart
bioAffinity CyPath Lung Test Sales Surge Sharply - TipRanks
TradingKey - TradingKey
bioAffinity reports 300% jump in lung test sales in April By Investing.com - Investing.com Australia
bioAffinity Reports Record Monthly CyPath Lung Unit Sales, April Up Nearly 300% - TradingView
Record CyPath Lung growth at bioAffinity (NASDAQ: BIAF) with April unit sales up nearly 300% - Stock Titan
bioAffinity Technologies, Inc. 2026 Q1 10-Q Filing: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
bioAffinity Technologies reports net loss of USD 3.6M in Q1 2026 - Medical Buyer
0.56%
0.44%
자본화:
|
볼륨(24시간):